Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

433.37 +2.16 (+0.50%)
Streaming Delayed Price Updated: 1:44 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. 
Via Investor's Business Daily
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline. 
Via Benzinga
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust... 
Via MarketMinute
Topics Artificial Intelligence Economy
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Via The Motley Fool
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Why Madrigal Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug. 
Via Investor's Business Daily
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth. 
Via Benzinga
Billionaire Investor Buys Google And This Gold Miner Stock
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet. 
Via Benzinga
Madrigal (MDGL) Q2 Revenue Soars 1,313%
Via The Motley Fool
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market. 
Via Chartmill
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August. 
Via Benzinga
5 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Via The Motley Fool
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,... 
Via Stocktwits
Topics Death
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations. 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week
Via The Motley Fool
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
Top 3 Health Care Stocks That May Dip This Month
 
Via Benzinga
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst
Via The Motley Fool
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
Via The Motley Fool
MDGL: A Promising Play In The Weight Loss Drug Space
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now... 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.